Antithrombotic peptides
Peptides designed to mimic PF4 and bind to multiple antibody regions disrupt the antibody/PF4 interaction, addressing the limitations of current treatments for HIT and VITT by preventing blood clots and improving patient outcomes.
Patent Information
- Application Number
- PCT/AU2026/050455
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for heparin-induced thrombocytopenia (HIT), vaccine-induced thrombotic thrombocytopenia (VITT), and VITT-like diseases are inadequate, relying on blood thinner administration with high bleeding risks and lack a directed approach to prevent or disassemble antibody/platelet factor 4 (PF4) immune complexes, leading to catastrophic blood clots.
Development of peptides with specific binding sequences that mimic PF4, allowing simultaneous binding to multiple regions of HIT or VITT antibodies, disrupting the formation of immune complexes by blocking the antibody/PF4 interaction.
The peptides effectively prevent platelet aggregation and thrombosis by blocking antibody binding to PF4, reducing the risk of blood clots and improving patient outcomes without the bleeding risks associated with current treatments.
Smart Images

Figure IMGF000019_0001 
Figure IMGF000009_0001_TABLE 
Figure 00000024_0000
Abstract
Description
Antithrombotic peptidesCross-reference to related applications
[0001] The present application claims priority to Australian Provisional Patent Application No.2025901736, filed 7 May 2025, the entire disclosure of which is incorporated herein by crossreference.Technical field
[0002] The present disclosure broadly relates to antithrombotic peptides and their use in treating heparin induced thrombocytopenia (HIT), vaccine induced thrombotic thrombocytopenia (VITT) and VITT-like diseases.Background
[0003] Any discussion of the prior art throughout this specification should in no way be considered as an admission that such prior art is widely known or forms part of the common general knowledge in the field.
[0004] HIT, VITT and VITT-like diseases are life-threatening immune reactions to heparin (HIT), the COVID-19 adenoviral vaccine (VITT), and to adenoviral infection (VITT-like diseases).
[0005] Approximately 3.5 million hospitalised patients will receive heparin in Australia per year (Australian Institute of Health and Welfare, 2021-2022) with an estimated 30,000 patients developing HIT. Without treatment, HIT has a mortality rate of 20%, and an additional 10% of patients require amputations.
[0006] The immune reaction in HIT, VITT and VITT-like disease involves the generation of antibodies against the self-protein platelet factor 4 (PF4). These antibodies and PF4 assemble into immune complexes which activate cells in the blood (platelets, neutrophils, monocytes) and damage the endothelial lining of the vessels causing catastrophic blood clots. These can require limb amputations and can in some instances be fatal. Treatment relies on cessation of the trigger (i.e. heparin or a vaccine) and the administration of blood thinners, which has a high risk of bleeding. However, there is no directed treatment available to date which can prevent or dis-assemble the antibody / PF4 immune complexes. Disrupting the formation of the immune complex would be expected to prevent the development of blood clots and improve outcomes in patients with HIT, VITT and VITT-like conditions.ME..963227530.
[0007] There is a need for improved treatments for HIT, VITT and VITT-like diseases.Summary
[0008] In a first aspect, there is provided a peptide comprising a first and a second binding peptide sequence joined by a spacer, wherein:• the first binding peptide sequence is capable of binding to a first region in a HIT or VITT antibody which is capable of binding to PF4, and• the second binding peptide sequence is capable of binding to a second region in the antibody, and• the spacer has a length sufficient to allow simultaneous binding of the first binding peptide sequence to the first region and the second binding peptide sequence to the second region.
[0009] The following options may be used in conjunction with the first aspect, either individually or in any suitable combination.
[0010] In one option, the first binding peptide sequence is PLYKKIIKK or a conservative variant thereof and the second binding peptide sequence is RH or a conservative variant thereof. In this instance, the peptide may have a length of at least about 10A. It may have a length of about 10 to about 15A. It may have a length of from about 10 to about 11 A. It may have a length of about 10.5A.
[0011] In another option, the first binding peptide sequence is RH or a conservative variant thereof and the second binding peptide sequence is KNG or a conservative variant thereof. In this instance the spacer may have a length of at least about 4A. It may have a length of about 4 to about 10A. It may have a length of about 4 to about 5A. It may have a length of about 4.1 A.
[0012] The peptide may additionally comprise a third binding peptide sequence which is capable of binding to a third region in the antibody, said third binding peptide sequence being joined to the second binding peptide sequence by a second spacer, said second spacer having a length sufficient to allow simultaneous binding of the second binding peptide sequence to the second region and the third binding peptide sequence to the third region. In the event that the first binding peptide sequence is PLYKKIIKK or a conservative variant thereof and the second binding peptide sequence is RH or a conservative variant thereof, the third binding peptide sequence may be KNG or a conservative variant thereof. TheME__963227630__1spacer may have a length of at least about 10A. The second spacer may have a length of at least about 4A.
[0013] The spacer and, if present, the second spacer may both be peptides. Alternatively one or both may be non-peptides.
[0014] The peptide may be PLYKKIIKKGPRHGKNG, PLYKKIIKKGGRHGGKNG, or a conservative variant thereof.
[0015] In an embodiment there is provided a peptide comprising a first and a second binding peptide sequence joined by a spacer, and a third binding peptide sequence joined to the second binding peptide sequence by a second spacer wherein:• the first binding peptide sequence is capable of binding to a first region in a HIT or VITT antibody which is capable of binding to PF4, and• the second binding peptide sequence is capable of binding to a second region in the antibody,• the third binding peptide sequence is capable of binding to a third region in the antibody, and• the spacer and the second spacer each has a length sufficient to allow simultaneous binding of the first binding peptide sequence to the first region and the second binding peptide sequence to the second region and the third binding sequence to the third region.
[0016] In another embodiment there is provided a peptide comprising a PLYKKIIKK peptide sequence, or a conservative variant thereof, and an RH peptide sequence, or a conservative variant thereof, joined by a spacer, and a KNG peptide sequence or a conservative variant thereof joined to the RH peptide sequence, or a conservative variant thereof, by a second spacer, wherein the spacer has a length between about 10 and about 11 A and the second spacer has a length between about 4 and about 5A.
[0017] In a further embodiment there is provided a peptide comprising a PLYKKIIKK peptide sequence, or a conservative variant thereof, and an RH peptide sequence, or a conservative variant thereof, joined by a spacer, and a KNG sequence, or a conservative variant thereof, joined to the RH peptide sequence, or a conservative variant thereof, by a second spacer, wherein:ME..963227530.• the spacer has a length between about 10 and about 11 and the second spacer has a length between about 4 and about 5A, and• the N-terminus of the peptide is P and the C-terminus of the peptide is G.
[0018] In a second aspect there is provided a pharmaceutical composition comprising a peptide according to the first aspect and at least one pharmaceutically acceptable carrier or adjuvant.
[0019] In a third aspect there is provided a method for treating or preventing HIT, VITT or VITT-like disease comprising administering to a subject in need thereof a clinically effective amount of a peptide according to the first aspect or a pharmaceutical composition according to the second aspect.
[0020] In a fourth aspect there is provided use of a peptide according to the first aspect or a pharmaceutical composition according to the second aspect in treating or preventing HIT, VITT or VITT-like disease in a subject.
[0021] In a fifth aspect there is provided use of a peptide according to the first aspect in the manufacture of a medicament for treating or preventing HIT, VITT or VITT-like disease in a subject.
[0022] In a sixth aspect of the invention there is provided a peptide according to the first aspect or a pharmaceutical composition according to the second aspect for treating or preventing HIT, VITT or VITT-like disease in a subject.
[0023] In a seventh aspect there is provided a peptide according to the first aspect or a pharmaceutical composition according to the second aspect when used for treating or preventing HIT, VITT or VITT-like disease in a subject.Brief Description of the Drawings
[0024] Figure 1. Identification of potential VITT antibody-binding domains on the PF4 protein. A. Based on a mutagenesis study by Huynh et al. (Nature, volume 596, pp. 565-569 (2021)), this panel displays the critical residues and their flanking amino acids involved in interactions with VITT antibodies. These residues are depicted in stick representation with arrows indicating their configuration in the final peptide inhibitor constructs. B. This panel measures the distances between three distinct domains on the PF4 surface that interact with VITT antibodies, found to be 10.5 A and 4.1 A apart, respectively.ME..963227530.
[0025] Figure 2. Peptide 1 and peptide 2 decrease platelet aggregation induced by VITT serum in the Multiplate. A. Area under curve (AU) of platelet aggregation over time (sec) after incubation of whole blood with VITT serum in the presence DMSO (vehicle control), 1 pM, 10 pM and 100 pM of peptide 2, and monoclonal antibody IV.3 (10 pg / ml). Each condition was performed in duplicate. B. Dose response of platelet aggregation by Multiplate to increasing concentrations of peptide 1 and peptide 2. Average Mean ± SD is shown. Two-way ANOVA ***P<0.001.
[0026] Figure 3. Peptide 2 decreases fibrin deposition and platelet adhesion. A.Endothelialised microfluidic chips were stimulated with TNF-a for 4h and incubated with Peptide 2 or Control peptide, anti-PF4 antibody KKO, heparin and PF4 at 37° for 1h. Then perfused with blood at shear rate of 100 sec1for up to 15 min. Fibrin was stained with antifibrin Alexa 594 and platelets with anti-CD41 FITC. Panels show end point confocal images of representative thrombus of three individual experiments, using three different blood donors imaged with 20x objective. Scale bar: 20pm. B. Fibrin and C. Platelet normalised area under the curve (AUC) of overall surface area coverage (pm2) against TNF-a and control peptide test group (n=3). Unpaired t-test. Mean ± SD is shown. *P<0.05; ****p<0.0001.
[0027] Figure 4. Relative reduction of platelet count over time of mice in Example 2. The marker • denotes the treatment group. The marker O denotes the control group.Description of embodiments
[0028] The inventors have surprisingly found that peptides may be constructed to mimic PF4. These peptides can therefore bind effectively with antibodies that complex with PF4 by binding to their active binding sites. In the absence of these peptides, the antibodies can bind to PF4 in order to initiate HIT, VITT and VITT-like disease.
[0029] By understanding the chemistry of the binding sites, the inventors have successfully generated suitable binding peptides and have demonstrated their effectiveness in combatting HIT, VITT and VITT-like disease. Thus the binding of these peptides to anti-PF4 antibodies (i.e. those generated in the course of HIT, VITT and VITT-like diseases), in particular to the specific binding sites of the antibodies, can block binding to PF4 itself and therefore prevent or alleviate HIT, VITT and VITT-like disease.
[0030] The binding sites of HITT / VITT antibodies to PF4 are illustrated in Figure 1. It is considered that residues Arg22, His23, Glu28, Lys46, Asn47, Lys50, Lys62, and Lys66 within PF4 may be important for interactions with the antibodies. In the present design, theME__963227630__1domains within PF4 that include Arg22, His23, Lys46, Asn47, Lys62, and Lys66 residues were extrapolated and assembled through GG and / or PG short amino acid spacers. As illustrated in Figure 1, the "PLYKKIIKK" stretch is approximately 10 angstroms away from the "RH" stretch. A 2- or 3-amino acid spacer was proposed to link these two stretches. Meanwhile, the distance between the "RH" and "KNG" stretches is about 4 angstroms; therefore, a 1- or 2-amino acid spacer was considered suitable. In general, spacers containing repeated G and S / A amino acids are typically used for bioconjugation. However, the inventors noted a sharp turn in direction between the 'PLYKKIIKK' and 'RH' stretches in the PF4 crystal structure. Therefore, proline was introduced into one of the constructs to facilitate this directional change. Nonetheless, the construct containing the proline and the construct where the proline was replaced by glycine exhibited comparable biological activities.
[0031] In order to enable more effective binding, it is useful to have amino acids in the peptide binding to at least two binding sites of the antibody, optionally to three binding sites. The binding amino acids should be connected by spacers which have a length that allows them to bind to the binding sites simultaneously. Thus, for example, if the spacer is too short, once one of the amino acids has bound to a binding site of the antibody, another amino acid would be unable to reach a corresponding other binding site on the antibody. In this case, the binding would be by means of only a single amino acid, and would therefore be weaker.
[0032] Spacers may be any suitable spacers that are of suitable length and are capable of reacting with both an N-terminal and a C-terminal of an amino acid. Short peptide sequences are suitable for this, and their length can conveniently be tailored as required by varying the number of amino acids in the spacer. Where the spacer comprises one or more amino acids, these may be natural or non-natural amino acids, including D-amino acids, N-methylated amino acids, p-amino acids, peptidomimetic residues, or any other chemically modified amino acids. However other types of spacer may also be used, for example hydrocarbon chains or polyether chains terminated with suitable reactive groups. Accordingly PEG and alkyl chains and other small-molecule linkers of appropriate lengths that can effectively bridge the 10.5 and 4.1 A distances required to connect the peptide stretches may be used as spacers. The skilled person will readily understand the reactive groups capable of bonding to amines and to carboxyl groups in order to construct the mimics described herein. For example, alkyl halide or acyl halide groups are capable of reacting with amines and amines or alcohols are capable of reacting with carboxyl groups in coupling reactions. Click chemistry, using functional group combinations such as azides and alkynes (including both metal catalysed and strain-promoted cycloaddition), or tetrazine and trans-cyclooctene, orME..963227530.other bioconjugation reactions such as oxime or hydrazone formation, or maleimide-thiol conjugation may also be used for these reactions. Peptide spacers are convenient, since they can be conveniently made using routine peptide synthesis methods.
[0033] Either end of a peptide according to this invention may be the N-terminus, and the other may be the C-terminus. In particular, the N-terminus of the peptides of the invention may be P. It may be PLYKKIIKK. The C-terminus of the peptides may be G. It may be KNG. Alternatively, the N-terminus may be G and the C-terminus may be P. In the event that a spacer between two peptide sequences is an amino acid or a spacer peptide sequence, the N-terminus of one of the peptide sequences must be coupled to the C-terminus of the spacer peptide sequence, and the N-terminus of the spacer peptide sequence must be coupled to the C-terminus of the other peptide sequence. More generally, in any of the peptides or peptide sequences or amino acids described herein, either end may be the C-terminus and the other end will then be the N-terminus.
[0034] If non-peptide spacers are used, both termini of the peptide may be C or both may be N. In this instance, it is possible that the C-terminus of one peptide sequence is joined via the spacer to the C-terminus of another peptide sequence or that the N-terminus of one peptide sequence is joined via the spacer to the N-terminus of another peptide sequence. It is however also possible that the C-terminus of one peptide sequence is joined via a non-peptide spacer to the N-terminus of another peptide sequence, so that one terminus of the peptide is C and the other is N.
[0035] The peptide according to this invention may linear, or it may be cyclic. It may be cyclised head-to-tail (i.e. whereby the first residue of the first binding peptide sequence is joined directly to the distal residue of the second or, where present, the third binding peptide sequence). Alternatively, it may be cyclised via an additional spacer as described above (i.e. whereby the first residue of the first binding peptide sequence is joined by an additional spacer to the distal residue of the second or, where present, the third binding peptide sequence).
[0036] In order to achieve sufficient binding strength to the antibody, it is preferable to have at least two separate binding sequences in the peptide mimic, each being capable of binding to a separate portion of the antibody. These should be separated by a spacer which has a suitable length to allow both of the binding sequences to bind to the corresponding portions of the antibody.ME..963227530.
[0037] In one example, one of the binding sequences is PLYKKIIKK and the other binding sequence is RH. In this instance, the spacer should be at least about 10A in length, or at least about 10.5A, to allow the two binding sequences to bind to the antibody simultaneously. The length may be from about 10 to about 15A, or from about 10.5 to about 15A, or from about 10 to 14, 10 to 13, 10 to 12 or 10 to 11 A, or from about 10.5 to 14, 10.5 to 13, 10.5 to 12 or 10.5 to HA e.g. about 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5 or 15A. In some cases the length may be greater than about 15A.
[0038] In another example, one of the binding sequences is RH and the other binding sequence is KNG. In this instance, the spacer should be at least about 4A in length, or at least about 4.1 A in length, to allow the two binding sequences to bind to the antibody simultaneously. The length may be from about 4 to about 10A, or about 4 to 9, 4 to 8, 4 to 7, 4 to 6, 4 to 5 or 4 to 4.5A, or about 4.1 to about 10A, or about 4.1 to 9, 4.1 to 8, 4.1 to 7, 4.1 to 6, 4.1 to 5 or 4.1 to 4.5A, e.g. about 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10A. In some cases the length may be greater than about 10A.
[0039] In another example, one of the binding sequences is PLYKKIIKK and the other binding sequence is KNG. In this instance the spacer should be at least about 12A, or at least about 13, 14 or 15A, to allow the two binding sequences to bind to the antibody simultaneously. The length may be from about 12 to about 16A, or about 12 to 15, 12 to 14, 12 to 13, 13 to 16, 14 to 16, 15 to 16, 13 to 15 or 13 to 14A, e.g. about 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5 or 16A. In some cases the length may be greater than about 16A.
[0040] In a further example, the binding sequences are PLYKKIIKK, RH and KNG, in which PLYKKIIKK is joined to RH by a first spacer and RH is joined to KNG by a second spacer. In this instance the first spacer should be at least about 10A in length, to allow PLYKKIIKK and RH to bind to the antibody simultaneously. The length may be from about 10 to about 15A, or from about 10 to 14, 10 to 13, 10 to 12 or 10 to 11 A, e.g. about 10, 10.5, 11, 11.5, 12, 1.5, 13, 13.5, 14, 14.5 or 15A. In some cases the length may be greater than about 15A. Additionally, the second spacer should be at least about 4A in length, to allow the KNG to bind to the antibody at the same time as both PLYKKIIKK and RH bind to the antibody. The length may be from about 4 to about 10 A, or about 4 to 9, 4 to 8, 4 to 7, 4 to 6, 4 to 5 or 4 to 4.5A, e.g. about 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10A. In some cases the length may be greater than about 10A.
[0041] In one embodiment, the binding sequences are PLYKKIIKK, RH and / or KNG as described above, or conservative variants thereof. A conservative variant is one in which 1, 2, 3, 4, 5, 6, 7, 8 or 9 amino acids of the PLYKKIIKK sequence, 1 or 2 amino acids of the RHME__963227630__1sequence and / or 1 , 2 or 3 amino acids of the KNG sequence are replaced with conservative amino acid substitutions. Relevant conservative amino acid substitutions are shown in Table 1 below.Amino acid Conservative substitutionP G, A, V, L, 1L G, A, V, 1Y F, WK H, R1 G, A, V, LR H, KH K, RN D, E, QG A, V, L, 1
[0042] Table 1.
[0043] It should be understood that, in the present context, the statement that two or three binding sequences bind, or are capable of binding, the antibody "simultaneously" should not be taken to mean that the process of attaching the binding sequences necessarily occurs at the same time, but rather that it is possible for both / all of the binding sequences to be attached to the antibody at the same time.
[0044] The peptides and any peptide sequences described herein may be made by standard peptide synthesis methods, for example using an automated peptide synthesiser. They may be made using solid phase synthesis methods.
[0045] Once the target peptide sequence is determined, the peptide may be synthesised on solid phase by sequentially adding amino acids until the complete sequence is formed. Alternatively, the separate binding peptide sequences and spacers (in the event that the spacers are peptide spacers) may be synthesised in this manner and they may be linked in the desired order.
[0046] An advanced peptide synthesiser may allow for full automation of these steps through programmable synthesis.
[0047] The C-terminal of the peptide may exist as either a C-terminal carboxylate or a C-terminal carboxamide, depending on the solid-phase resin used. Specifically, the commonly used chlorotrityl chloride resin yields peptides with a C-terminal carboxylate, while Rink Amide resin produces peptides with a C-terminal carboxamide.
[0048] In the event that the spacers are not peptides, they may be attached to amino acid residues in peptide sequences by well-known coupling methods. These may includeME__963227630__1attaching click pairs to the spacer and to the peptide sequence to which it is to be linked. These attachments may be achieved by standard organic chemical methods. An example of a click pair is an alkyne and an azide, which can be readily "clicked" to form a triazole linkage. In an example, RH is coupled to an alkane spacer where the H end is an N-terminus. In this instance, RH may be reacted with propynoic acid to produce the corresponding propynoamide. An alkyl halide may be reacted with sodium azide in order to produce the corresponding alkyl azide. The alkyl azide may then be clicked with the propynoamide to couple the two portions together. The skilled person will readily appreciate other ways to achieve such couplings, for example strain-promoted click chemistry, tetrazine click chemistry, and hydrazine / hydrazone click chemistry.
[0049] The peptides are useful in combatting antibody deactivation of PF4. They are therefore useful in treating HIT, VITT or VITT-like disease.
[0050] Those skilled in the art will recognise that compounds and pharmaceutical compositions of the disclosure may be administered via any route which delivers an effective amount of the compounds to the subject's blood stream. In general, the compounds and compositions may be administered by the parenteral (for example intravenous, subcutaneous or intramuscular) or rectal route. Administration may be systemic.
[0051] In general, suitable compositions may be prepared according to methods that are known to those of ordinary skill in the art and may include pharmaceutically acceptable carriers, diluents and / or excipients. The carriers, diluents and excipients must be "acceptable" in terms of being compatible with the other ingredients of the composition, and not deleterious to the recipient thereof.
[0052] Examples of pharmaceutically acceptable carriers or diluents include sterile, demineralised or distilled water, saline solution and DMSO (dimethylsulfoxide). Typically, the carrier or carriers will form from about 10% to about 99.9% by weight of the compositions.
[0053] Pharmaceutical compositions may be in a form suitable for administration by injection, in an aerosol form suitable for administration by inhalation, such as by intranasal inhalation or oral inhalation, in a form suitable for parenteral administration, that is, subcutaneous, intramuscular or intravenous injection. They may contain the peptide in a concentration of at least about 1pM, or at least about 2, 5, 10, 20, 50 or 100 pM, or from about 1 to about 200 pM, or from about 1 to 100, 1 to 50, 1 to 20, 1 to 10, 5 to 200, 10 to 200, 20 to 200, 50 to 100, 100 to 200, 10 to 100, 10 to 50, 50 to 100, 100 to 150 or 20 to 50 pM, e.g. about 1, 2,ME..963227530.3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190 or 200 pM.
[0054] For administration as an injectable solution or suspension, non-toxic parenterally acceptable diluents or carriers can include cyclodextrins (for example Captisol®) Cremophor®, Ringer's solution, isotonic saline, phosphate buffered saline, ethanol, DMSO and 1,2 propylene glycol. To aid injection and delivery, the compounds may also be added to PEG and non-PEGylated liposomes or micelles.
[0055] Adjuvants typically include emulsifiers, preservatives, bactericides and buffering agents.
[0056] Methods for preparing parenterally administrable compositions are known to those skilled in the art, and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, PA, the entirety of which is incorporated herein by reference.
[0057] In some embodiments the compositions are administered in the form of suppositories suitable for rectal administration of the peptides of the first aspect. These compositions are prepared by mixing the peptide with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the peptides of the first aspect. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.
[0058] For the purposes of the present disclosure, compounds and compositions may be administered to subjects either therapeutically or preventively. In a therapeutic application compositions are administered to a patient already suffering from HIT, VITT or VITT-like disease in an amount sufficient to cure, or at least partially arrest the condition and its complications. The composition should provide a quantity of the compound sufficient to effectively treat the subject.
[0059] The therapeutically effective amount for any particular subject will depend upon a variety of factors including: the composition in which the peptide is present; the age, body weight, general health, sex and diet of the subject; the time of administration; the route of administration; the rate of sequestration of the compound; the duration of the treatment; drugs used in combination or coincidental with the peptide, together with other related factors well known in medicine.ME..963227530.
[0060] Generally, an effective dosage is expected to be in the range of about 0.0001 mg to about 1000 mg per kg body weight per 24 hours; or, about 0.001 mg to about 750 mg per kg body weight per 24 hours; about 0.01 mg to about 500 mg per kg body weight per 24 hours; about 0.1 mg to about 500 mg per kg body weight per 24 hours; about 0.1 mg to about 250 mg per kg body weight per 24 hours; about 1.0 mg to about 250 mg per kg body weight per 24 hours. Commonly, an effective dose range is expected to be in the range about 1.0 mg to about 200 mg per kg body weight per 24 hours; about 1.0 mg to about 100 mg per kg body weight per 24 hours; about 1.0 mg to about 50 mg per kg body weight per 24 hours; about 1.0 mg to about 25 mg per kg body weight per 24 hours; about 5.0 mg to about 50 mg per kg body weight per 24 hours; about 5.0 mg to about 20 mg per kg body weight per 24 hours; or about 5.0 mg to about 15 mg per kg body weight per 24 hours.
[0061] Typically, in therapeutic applications, the treatment would be for the duration of the HIT, VITT or VITT-like disease.
[0062] Further, it will be apparent to one of ordinary skill in the art that the optimal quantity and spacing of individual dosages will be determined by the nature and severity of the HIT, VITT or VITT-like disease being treated, the form, route and site of administration, and the nature of the particular individual being treated. Also, such optimum conditions can be determined by conventional techniques.
[0063] The peptides of the invention may be used alone in the treatment of HIT, VITT or VITT-like disease, or alternatively in combination with other therapeutic agents as part of a combination therapy.
[0064] Combination therapy may involve the active agents being administered together, sequentially, or spaced apart as appropriate in each case. Combinations of active agents including the peptides of the disclosure may be synergistic.
[0065] The co-administration of peptides of the first aspect with other therapeutic agent(s) may be effected by the peptide being in the same unit dose form as the other therapeutic agent(s), or the peptide and the other therapeutic agent(s) may be present in individual and discrete unit dosage forms that are administered sequentially, at the same, or at a similar time. Sequential administration may be in any order as required, and may require an ongoing physiological effect of the first or initial agent to be current when the second or later agent is administered, especially where a cumulative or synergistic effect is desired. When administered separately, it may be preferred for the peptide and the other agent to be administered by the same route of administration, although it is not necessary for this to beME..963227530.so. In accordance with various embodiments of the present disclosure one or more peptides according to the invention may be included in combination therapy with one or more therapeutic agents.Definitions
[0066] The following are some definitions that may be helpful in understanding the description of the present disclosure. These are intended as general definitions and should in no way limit the scope of the present disclosure to those terms alone, but are put forth for a better understanding of the following description.
[0067] Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. The word "consist" or variations thereof will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, and the exclusion of any other element, integer or step, or group of elements, integers or steps. The term "consist essentially" or variations thereof will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, and the exclusion of any other intentionally added element, integer or step, or group of elements, integers or steps. The term "comprise" and variations thereof encompasses both "consist" and "consist essentially".
[0068] The terms "a" and "an" are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
[0069] In the context of this specification the term "about" is understood to refer to a range of numbers that a person of skill in the art would consider equivalent to the recited value in the context of achieving the same function or result. The term "about" may refer to ±10% of the recited value.
[0070] The term "may" is intended to include both positive and negative recitations unless the context indicates otherwise. Thus, for example, "A may be B" encompasses both "A is B" and "A is not B".
[0071] Any numerical range recited herein is intended to include all sub-ranges of the same numerical precision subsumed within the recited range. For example, a range of 1.0 to 5.0 is intended to include all sub-ranges between (and including) the recited minimum value ofME__963227630__11.0 and the recited maximum value of 5.0, that is, having a minimum value equal to or greater than 1.0 and a maximum value equal to or less than 5.0, such as 2.1 to 4.5. Any maximum numerical limitation recited herein is intended to include all lower numerical limitations subsumed therein and any minimum numerical limitation recited herein is intended to include all higher numerical limitations subsumed therein.
[0072] As used herein, the terms "peptide" and "peptide sequence" refer to a chain of between 1 and 50 amino acid units linked by amide bonds. In some instances, non-peptide spacers may be present within a peptide chain.
[0073] As used herein, "HIT" refers to type II heparin-induced thrombocytopenia, i.e. autoimmune heparin-induced thrombocytopenia.
[0074] The following letters are used in peptide sequences to denote specific amino acids: G - glycine, H - histidine, I - isoleucine, K - lysine, L - leucine, N - asparagine, P - proline, R - arginine, Y - tyrosine. Corresponding three letter codes are Gly - glycine, His - histidine, lie - isoleucine, Lys - lysine, Leu - leucine, Asn - asparagine, Pro - proline, Arg - arginine, Tyr - tyrosine.
[0075] In the context of this specification, the term "effective amount" includes a non-toxic but sufficient amount of an active compound to provide the stated effect. When used in reference to HIT, VITT or VITT-like disease, "effective amount" means an amount of a peptide of the first aspect that is required to reduce the incidence of, or risk of an individual experiencing the condition. Those skilled in the art will appreciate that the exact amount of a compound required will vary based on a number of factors and thus it is not possible to specify an exact "effective amount". However, for any given case an appropriate "effective amount" may be determined by one of ordinary skill in the art.
[0076] In the context of this specification, the term "therapeutically effective amount" includes a non-toxic but sufficient amount of an active compound to provide the desired therapeutic effect. Those skilled in the art will appreciate that the exact amount of a compound required will vary based on a number of factors and thus it is not possible to specify an exact "therapeutically effective amount". However, for any given case an appropriate "therapeutically effective amount" may be determined by one of ordinary skill in the art.
[0077] In the context of this specification, the terms "treating", "treatment", "preventing" and "prevention" refer to any and all uses that remedy the condition or symptoms thereof, prevent the establishment of the condition, or otherwise prevent, hinder, retard or reverse the progression of the condition or other undesirable symptoms in any way whatsoever. Thus,ME__963227630__1the terms "treating", "treatment", "preventing" and "prevention" and the like are to be considered in their broadest context. For example, treatment does not necessarily imply that a subject is treated until total recovery.
[0078] In the context of this specification, the term "subject" includes human and also nonhuman animals. Non-human animals may be primates. They may be mammals. They may be vertebrates. As such, in addition to being useful in the treatment of humans, the compounds of the present disclosure also find use in the treatment of non-human animals, for example mammals such as companion animals and farm animals. Non-limiting examples of companion animals and farm animals include dogs, cats, horses, cows, sheep and pigs.
[0079] In the context of this specification the term “administering” and variations of that term including “administer” and “administration”, includes contacting, applying, delivering or providing a compound or composition to an organism by any appropriate means.
[0080] Any description of prior art documents herein, or statements herein derived from or based on those documents, is not an admission that the documents or derived statements are part of the common general knowledge of the relevant art.
[0081] For the purposes of description, all documents referred to herein are hereby incorporated by reference in their entirety unless otherwise stated.Examples
[0082] The present disclosure is further described below by reference to the following nonlimiting examples.Example 1Design and synthesis of PF4 mimic peptides
[0083] The sequence of PF4 at the PF4-antibody interface was published by Huynh, et al. (J Thromb Haemost., 17(2), p. 389-399). Peptide sequences in three separate domains of PF4 that have been found critical for the binding of VITT and HIT antibodies were identified as RH (residue 21-22), KNG (residue 46-48) and PLYKKIIKK (residue 58-66) in PF4. These were linked with appropriate amino acid spacers to create peptide candidates (PF4 mimics #1 and #2), designed to disrupt the interaction between HIT or VITT antibodies and native PF4. Peptide synthesis was conducted using a solid phase peptide synthesiser.ME..963227530.
[0084] Chlorotrityl chloride resin was used to assemble PF4 mimic #1 and #2. As a consequence they both have C-terminal carboxylate. The first Fmoc-amino acid (4.0 equivalents relative to the resin loading) was loaded onto the chlorotrityl chloride resin using diisopropylethylamine (4.0 equivalents) in DMF. Subsequent amino acid couplings were performed using the Syro I Fully Automated Parallel Peptide Synthesizer (Biotage), with each SPPS cycle employing Fmoc-amino acid (5.0 equivalents), oxyma (ethyl cyanohydroxyiminoacetate, 5.5 equivalents), and diisopropylcarbodiimide (5.0 equivalents). Following the final Fmoc deprotection with 20% piperidine in DMF, the peptide-bound resin underwent acid deprotection and cleavage using trifluoroacetic acid, triisopropylsilane, and water (90:5:5, v / v / v) for 2 hours. The crude peptide was then precipitated with ether and purified via standard reversed-phase HPLC.
[0085] PF4 mimic #1 ("Peptide 1")Sequence: PLYKKIIKKGPRHGKNGWeight: 5.83 mg, Molecular weight: 1934 Da
[0086] PF4 mimic #2 ("Peptide 2")Sequence: PLYKKIIKKGGRHGGKNGWeight: 5.58 mg, Molecular weight: 1951 Da
[0087] Peptides were dissolved in DMSO for a stock solution of 100 mM.Functional platelet assay by multiplate assay
[0088] The effect of peptide 1 and peptide 2 on platelet aggregation, induced by anti-PF4 antibody (HIT or VITT antibody), was determined by the Multiplate assay. Whole blood in hirudin was received from HIT antibody-responsive donors (Morel-Kopp, et al. JTH, 2016).
[0089] Donor blood, 300 pl, was incubated with 150 pl normal saline, or peptide 1 or 2 in normal saline, within the Multiplate cell for 2 minutes at 37°C. The stock solutions of Peptides 1 and 2 were diluted in saline to achieve the desired working concentrations for assay testing. Monoclonal antibody IV.3, which blocks the human Fc gamma receptor Ila, was incubated with blood at 10 pg / ml. IV.3 is routinely used as an inhibitory antibody of the antibody-PF4 complex in diagnostic assays. However, IV.3 cannot be administered to humans as a therapeutic as it causes profound infusion reactions and thrombocytopenia in mice. VITT serum 150 pl was added to the cell and platelet aggregation was recorded over 6 min. TheME__963227630__1final concentration of peptide 1 and 2 was 100 pM. Platelet aggregation was determined as the area under the curve (AUC) on the Multiplate readout.In vitro thrombosis by Endo-chip
[0090] The effect of peptide 1 and peptide 2 on platelet adhesion and fibrin accumulation was measured by the Endo-chip assay (Dupuy, et al. Diagnostics, 2021).
[0091] Single channel PDMS devices were prepared, as described (Dupuy, et al. Bio Protoc, 2019). The channel of the PDMS device was coated with fibronectin 50 pg / mL. Human Umbilical Vein Endothelial Cells (HUVECs) were cultured in M199 media containing 20% FCS (fetal calf serum) and endothelial growth factors (M199 culture media), to confluency. HUVECs were detached, washed and resuspended at 20 x 106 cells / mL. The HUVEC suspension was perfused through the channel (6 pL) and left to incubate within the device for 30 min at 37°C, 5% CO2. The channel was then perfused with M199 culture media through the inlet to flush out non-attached cells, and the endothelial biochip was left to incubate for 2 hrs at 37°C, 5% CO2, with media changes every 30-60 min for at least 2 hrs to form a confluent monolayer. This device is the “Endo-chip”.
[0092] To examine the effect of HIT immune complex on human endothelium in regard to thrombus formation and endothelial activation, a combination of reagents was incubated with the endothelium prior to perfusion at 37°C for 1 hour. The reagents were anti-PF4 / heparin antibody (KKO) (100 pg / mL) or HIT IgG (100 pg / mL) or VITT IgG (100 pg / mL), purified mouse lgG1 (100 pg / mL, BD PharmingenTM) or control human IgG (100 pg / mL). For the formation of HIT immune complex, heparin (0.5 U / mL) and PF4 (25 pg / mL) was added. For the formation of the VITT immune complex only PF4 (25 pg / mL) was added. To examine the inhibitory effect of PF4 mimic peptide treatment on human endothelium, the stock solutions of Peptides 1 and 2 were diluted with saline to final concentration of 100 pM. They were then incubated on TNF-a (10 ng / mL) treated Endo-chip with anti-PF4 / heparin antibody (KKO) (100 pg / mL), heparin (0.5 U / mL) and PF4 (25 pg / mL) at 37°C for 1 hour prior to perfusion.
[0093] Whole blood was collected from a peripheral vein using a 21 G butterfly needle according to standard practice. Blood was collected into vacutainers containing 3.2 % sodium citrate (Becton- Dickinson) and used within 4 hours of collection.
[0094] Citrated whole blood was stained with an anti-CD41 antibody conjugated to FITC (fluorescein isothiocyanate) (0.5 pg / mL final concentration, P2 clone, Beckman-Coulter) and an anti-fibrin antibody conjugated to Alexa Fluor 594 (0.5 pg / mL final concentration, 59D8 clone). The blood was stained for 10 min prior to initiation of the experiment.ME__963227630__1
[0095] A syringe pump was connected to a 2 mL glass syringe, sealed with a 3-way stop-cock. The stop-cock was connected to medical-grade tubing with a metal pin bent at 90°, formed from a 18 G blunt syringe needle for connecting the tubing to the Endo-chip.
[0096] The stained blood was added to the inlet of the biochip at 100 pL aliquots, each time being recalcified with 1:100 volume of 1M CaCl2 (10 mM final concentration of CaCl2). To perfuse whole blood and expose endothelial cells and blood components to shear, the syringe pump was set to a flow rate of 11.74 pL / min. This corresponds to a shear rate of about 100 s'1(similar to blood shear rates in veins). In some instances, a flow rate of 93.92 pL / min was used to achieve a shear rate of 800 s-1(similar to blood shear rates in some arteries). Platelet and fibrin accumulation (in vitro thrombus) formation was measured about 5-12 pm above the plane of the endothelium. The formation of a thrombus was imaged on a Zeiss 880 confocal microscope.Data analysis
[0097] Data was quantitatively analysed with a thresholding and area measurement macro to assess the thrombus area coverage during the perfusion. Statistical analysis of dose curves was by two-way ANOVA. Analysis of multiple comparisons was by one-way ANOVA with Dunnett’s post-test. Statistical significance was set at p<0.05. Data was analysed using Prism 7.0 software (GraphPad, La Jolla, CA).
[0098] Peptide 1 and peptide 2, but not control peptide, inhibited platelet aggregation induced by patient serum containing anti-PF4 antibody.
[0099] Peptide 1 inhibited platelet aggregation by 62% at 100 pM dose whereas Peptide 2 inhibited platelet aggregation by 73% at 100 pM dose. This percentage inhibition was comparable to the inhibition of platelet aggregation by monoclonal antibody IV.3 (Figure 2).Peptide 2 inhibited in vitro thrombosis on the Endo-chip
[0100] Fibrin and platelet deposition were significantly decreased in the presence of peptide 2 versus the control peptide treatment (Figure 3). Moreover, kinetic curve analysis demonstrated a significant decrease / delay in fibrin and platelet accumulation with the PF4 peptide compared to the control group.ME..963227530.Example 2Mouse model of HIT
[0101] The HIT condition was induced in hPF4 / FcvRlla double transgenic mice by i.v. administration of the HIT antibody KKO (10 pg / g) and heparin i.p. (1 U / g) in the presence of vehicle (DMSO, 3 pL per mouse). A treatment group (n=2) was administered an equivalent to 50 pM of Peptide 1 in DMSO (assuming a blood volume of 1.5 mL per mouse). A control group (n=2) did not receive any treatment. Platelets were counted by flow cytometry at time 0 (before treatment) and at 2 h and 4 h after heparin injection. Mice in the control group had a 70% reduction in their platelet count whereas mice in the treatment group had a 20% reduction in their platelet count. See Figure 4.Example 3Cyclic peptideH2N
[0102] Peptide 1 cyclic variant.
[0103] Solid-phase peptide synthesis of linear peptide: The linear Peptide 1 PLYKKIIKKGPRHGKNG sequence was assembled by standard Fmoc-based solid-phase peptide synthesis.
[0104] For Fmoc deprotection, a solution of piperidine in DMF (20% v / v, 5 mL) was added to the resin and the mixture was agitated for 3 min. The resin was drained, and the deprotection step was repeated once. The resin was then washed sequentially with DMF (5 x 5 mL), CH2CI2(5 x 5 mL), and DMF (5 x 5 mL).ME_963227630_1
[0105] For amino acid coupling, a solution of the Fmoc-protected amino acid, Fmoc-protected spacer, or other Fmoc-protected building block (1.00 mmol, 4.0 equiv.), diisopropylcarbodiimide (DIC; 126 mg, 0.16 mL, 1.00 mmol), and Oxyma Pure (142 mg, 1.00 mmol) in DMF (2.5 mL) was added to the resin. The reaction mixture was agitated for 1 h at room temperature. Following coupling, the resin was drained and washed with DMF.
[0106] A capping step was then performed by adding a solution of acetic anhydride / pyridine (1:9 v / v, 5 mL) to the resin and agitating for 5 min. The resin was drained and washed sequentially with DMF (5 x 5 mL), CH2CI2(5 x 5 mL), and DMF (5 x 5 mL). The deprotection, coupling, washing, and capping cycles were repeated until the peptide sequence was fully assembled.
[0107] General procedure for peptide cyclisation: After assembly of the linear peptide sequence, the protected peptide with an Fmoc protecting group on solid-phase was first added with a solution of piperidine in DMF (20% v / v, 5 mL) followed by agitating the mixture for 3 min. The resin was drained, and the deprotection step was repeated once. The resin was then washed sequentially with DMF (5 x 5 mL), CH2CI2(5 x 5 mL), and DMF (5 x 5 mL).
[0108] The resulting resin-bound protected peptide was treated with a solution of HFIP / CH2CI2(3:7 v / v, 5 mL). The mixture was incubated for 1 h at room temperature with vigorous agitation to release the protected peptide from the resin. The resulting solution was collected and concentrated under a stream of nitrogen gas. The protected linear peptide was then redissolved in DMF (5 mL), followed by the addition of diisopropylcarbodiimide (DIC; 126 mg, 0.16 mL, 1.00 mmol) and Oxyma Pure (142 mg, 1.00 mmol). The reaction mixture was agitated for 1 h at room temperature to promote cyclisation. The solvent was then removed under a stream of nitrogen gas.
[0109] Global cleavage and deprotection were performed by treating the crude cyclised peptide with a cleavage cocktail composed of TFA / TIS / water (90:5:5 v / v / v). After 2 h at room temperature, the reaction mixture was added dropwise to ice-cold diethyl ether to precipitate the peptide. The suspension was centrifuged, and the ether was removed.
[0110] The resulting crude peptide was purified by reverse-phase HPLC using a gradient of 0-15% acetonitrile in water over 40 minutes containing 0.1% trifluoroacetic acid to afford the purified Peptide 1 cyclic variant (4.2% yield, 2 mg).Industrial applicability
[0111] The present disclosure is useful in treatment of HIT, VITT and VITT-like disease.ME__963227630__1
[0112] Those skilled in the art will appreciate that the disclosure described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the disclosure includes all such variations and modifications. The disclosure also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps, features, compositions and compounds.ME..963227530.
Claims
Claims:
1. A peptide comprising a first and a second binding peptide sequence joined by a spacer,wherein:the first binding peptide sequence is capable of binding to a first region in a HIT or VITT antibody which is capable of binding to PF4, andthe second binding peptide sequence is capable of binding to a second region in the antibody, andthe spacer has a length sufficient to allow simultaneous binding of the first binding peptide sequence to the first region and the second binding peptide sequence to the second region.
2. The peptide of claim 1 wherein the first binding peptide sequence is PLYKKIIKK or a conservative variant thereof and the second binding peptide sequence is RH or a conservative variant thereof.
3. The peptide of claim 2 wherein the spacer has a length of at least about 10A.
4. The peptide of claim 2 or claim 3 wherein the spacer has a length of from about 10 to about 11 A.
5. The peptide of claim 1 wherein the first binding peptide sequence is RH or a conservative variant thereof and the second binding peptide sequence is KNG or a conservative variant thereof.
6. The peptide of claim 5 wherein the spacer has a length of at least about 4A.
7. The peptide of claim 5 or claim 6 wherein the spacer has a length of from about 4A to about 5A.
8. The peptide of any one of claims 1 to 7 additionally comprising a third binding peptide sequence which is capable of binding to a third region in the antibody, said third binding peptide sequence being joined to the second binding peptide sequence by a second spacer, said second spacer having a length sufficient to allow simultaneous binding of the second binding peptide sequence to the second region and the third binding peptide sequence to the third region.ME..963227530.
9. The peptide of claim 8 wherein the third peptide sequence is KNG or a conservative variant thereof.
10. The peptide of claim 8 or claim 9 wherein the spacer has a length of at least about 10A.
11. The peptide of any one of claims 8 to 10 wherein the second spacer has a length of at least about 4A.
12. The peptide of any one of claims 1 to 11 wherein the spacer and, if present, the second spacer are both peptides.
13. The peptide of any one of claims 1 to 12 which is PLYKKIIKKGPRHGKNG, PLYKKIIKKGGRHGGKNG, or a conservative variant thereof.
14. A pharmaceutical composition comprising a peptide according to any one of claims 1 to 13 and at least one pharmaceutically acceptable carrier or adjuvant.
15. A method for treating or preventing HIT, VITT or VITT-like disease comprising administering to a subject in need thereof a clinically effective amount of a peptide according to any one of claims 1 to 13 or a pharmaceutical composition according to claim 14.
16. Use of a peptide according to any one of claims 1 to 13 or a pharmaceutical composition according to claim 14 in treating or preventing HIT, VITT or VITT-like disease in a subject.
17. Use of a peptide according to any one of claims 1 to 13 in the manufacture of a medicament for treating or preventing HIT, VITT or VITT-like disease in a subject.
18. A peptide according to any one of claims 1 to 13 or a pharmaceutical composition according to claim 14 for treating or preventing HIT, VITT or VITT-like disease in a subject.
19. A peptide according to any one of claims 1 to 13 or a pharmaceutical composition according to claim 14 when used for treating or preventing HIT, VITT or VITT-like disease in a subject.ME..963227530.
